Business
Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery
Royalty revenue contribution expected to begin as early as 2030 Initial partner targets include derisked MoAs that are approved blockbusters today Highly
About this update from Halozyme Therapeutics, Inc.
[{"type":"text","content":"\n Royalty revenue contribution expected to begin as early as 2030\n \n \n Initial partner targets include derisked MoAs that are approved blockbusters today\n \n \n Highly scalable licensing model and long duration IP into 2040s; potential for individual product IP extension through proprietary reformulation\n \n \n Two of Elektrofi's partners projected to begin Hypercon™ formulated product clinical development by year end 2026, or earlier\n \n \n SAN DIEGO, Nov. 18, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (\"Halozyme\") today announced the successful completion of its acquisition of Elektrofi, Inc. (\"Elektrofi\"), a biopharmaceutical company with a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon™.\n The transaction follows the expiration of the Hart-Scott-Rodino waiting period and satisfaction of all closing conditions.\n \"Completing the acquisition of Elektrofi is a strategic milestone in our mission to expand Halozyme's drug delivery technology offerings to biopharma companies. With the addition of the Hypercon ultra-high concentration microparticle formulation technology, we will be able to offer partners a diverse portfolio of drug delivery solutions. The acquisition adds an additional high growth potential, royalty revenue business that is complementary to the strong ENHANZE royalty business to drive long-term royalty growth for decades to come,\" said Dr. Helen Torley, President and Chief Executive of Halozyme. \"Most importantly, this acquisition reinforces our mission to transform how vital medicines are delivered, ensuring treatments fit seamlessly into a patient's life, rather than patients having to shape their lives around treatment.\"\n \"We are excited to welcome the talented Elektrofi team to Halozyme. We look forward to supporting their continued innovation and execution as we now advance the two programs into the clinic before year end 2026, a key step toward unlocking the potential of the Hypercon platform and delivering long-term value to our partners and shareholders,\" concluded Dr. Torley.\n The Hypercon™ technology is an innovative microparticle approach that sets a new standard in the pursuit of hyper concentration, enabling high protein concentrations while maintaining syringeability, which is the ability to inject smoo...